
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio Inc. is benefiting from exceptionally positive sentiment among key opinion leaders (KOLs), particularly regarding the anticipated success of its pulmonary arterial hypertension (PAH) treatment, PROSERA, which is expected to demonstrate significant treatment effects. The Phase 2 TORREY data highlighted consistent benefits in multiple endpoints, showcasing the drug's potential efficacy, safety, and durability, thus strengthening the company's standing in the competitive biopharmaceutical landscape. Additionally, renewed investor interest stemming from recent conferences and optimistic discussions surrounding Gossamer Bio's pipeline further underpins the positive outlook for the company's stock.
Bears say
Gossamer Bio has a negative outlook primarily due to the market's mispricing of seralutinib's probability of success, which suggests an overestimation of the asset's value despite recent stock appreciation. The lack of concrete financial progress or regulatory advancement for the pipeline products raises concerns about the viability of the company's strategic focus in therapeutics. Additionally, the continued uncertainty surrounding seralutinib’s clinical development could adversely affect investor confidence and the company's long-term financial stability.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares